Home
Drugs
Durvalumab
Clinical Trials

Clinical Trials Related to Durvalumab

Related studies linked through entity extraction aliases.

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Status: RECRUITING
Phase: PHASE2

RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

Status: COMPLETED
Phase: N/A

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Status: RECRUITING
Phase: PHASE1/PHASE2

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

Status: COMPLETED
Phase: PHASE3

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Status: TERMINATED
Phase: PHASE1

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Status: RECRUITING
Phase: PHASE2

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Status: RECRUITING
Phase: PHASE1/PHASE2

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Status: WITHDRAWN
Phase: PHASE1

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Status: RECRUITING
Phase: PHASE2

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Status: RECRUITING
Phase: PHASE2

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

TRUDI: TDXD+Durva in HER2+/Low IBC

Status: RECRUITING
Phase: PHASE2

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Status: WITHDRAWN
Phase: PHASE2

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Status: RECRUITING
Phase: PHASE1